Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Deals
  5. Corporate Activity
  6. Merger

Merger

Thumbnail
March 15, 2023

Activist investor answers call for Jounce's cash

February 23, 2023

Conditions are ripe for reverse mergers

Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?

Article image
Vantage logo
February 09, 2023

Biopharma and Medtech Review 2022

Article image
Vantage logo
February 06, 2023

The slow death of the medtech Spac deal

The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.

Article image
Vantage logo
January 10, 2023

Amgen saves biopharma’s buyout year

December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.

Article image
Vantage logo
November 09, 2022

Takeout premiums hold up, but that’s not the whole story

Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.

Article image
Vantage logo
October 07, 2022

Nektar and Puretech make strange bedfellows

It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.

Article image
Vantage logo
October 05, 2022

No big bang for biopharma buyouts

Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.

Article image
Vantage logo
July 20, 2022

The other shoe finally drops for device dealmaking

A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.

Article image
Vantage logo
May 23, 2022

Diagnostics beat implants in the race to market

Roche had the most innovative approvals over the last five years – but took second place in terms of speed.

Article image
Vantage logo
May 06, 2022

For medtechs seeking deals, it’s hurry up and wait

Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up